Expand AUTL Menu
AUTL MENU

AUTL Latest Press Releases

-- April 7, 2026 --

Autolus Therapeutics to Participate in Upcoming Investor Conferences Globe Newswire 7:00 AM

-- March 27, 2026 --

Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates Globe Newswire 7:00 AM

-- March 16, 2026 --

Autolus Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 27, 2026 Globe Newswire 4:10 PM

-- February 24, 2026 --

Autolus Therapeutics to Participate in Upcoming Investor Conferences Globe Newswire 7:00 AM

-- February 5, 2026 --

The $71 Billion Cancer Shift: Why The FDA Is Speeding Up Globe Newswire 9:26 AM

-- February 4, 2026 --

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 8:57 AM

-- January 12, 2026 --

Autolus Therapeutics Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Net Product Revenue, Pipeline Advancements and Outlook for 2026 Globe Newswire 7:00 AM

-- January 6, 2026 --

Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL (obe-cel) on the Cellares Cell ShuttleTM Platform Business Wire 9:00 AM
Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL (obe-cel) on the Cellares Cell Shuttle Platform Globe Newswire 9:00 AM

-- December 8, 2025 --

Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025 Globe Newswire 4:05 PM
Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025 Globe Newswire 8:35 AM

-- December 1, 2025 --

Autolus Therapeutics Appoints Ryan Richardson to Board of Directors Globe Newswire 7:00 AM

-- November 25, 2025 --

NICE Recommends AUCATZYL (obecabtagene autoleucel) as a Treatment Option for Adult Patients (=26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) Globe Newswire 4:00 AM
Market Data Delayed 15 Minutes